Eli Lilly and Company (LLY) 73.60 $LLY
The Next Stock Warren Buffett May Sell
Todd Campbell, Dan Caplinger, and George Budwell, The Motley Fool - Motley Fool - Sat Mar 05, 6:21AM CST
Warren Buffett is legendary for his long-term buy-and-hold approach to investing, and as a result, investors big and small closely watch his buying and selling activity. There's no crystal ball that will tell all of us what his next move will be, but...
JNJ: 106.50 (-0.15), LLY: 73.60 (+0.35), SNY: 39.81 (+0.19), VZ: 51.81 (-0.08)
Novo Nordisk Pops As Diabetes Drug Cuts Heart Disease Deaths
at Investor's Business Daily - Fri Mar 04, 3:26PM CST
Shares of diabetes giant Novo Nordisk (NVO) jumped Friday after the company said its drug Victoza reduced heart attacks and strokes. Novo released few details about the results of the study, which it's saving for the next American Diabetes...
JNJ: 106.50 (-0.15), NVO: 56.75 (+4.15), MRK: 52.08 (-0.02), AZN: 28.87 (+0.13), LLY: 73.60 (+0.35), SNY: 39.81 (+0.19)
Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis
PR Newswire - Fri Mar 04, 3:15PM CST
Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week, compared to patients treated with etanercept or placebo. Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.
LLY: 73.60 (+0.35)
Drug Company Executives Make the Best Connections
at The Street - Fri Mar 04, 2:07PM CST
An analysis from business information service BoardEx shows that the CEOs of healthcare and pharma companies have professional networks about 30% larger than the average S&P 500 CEO network.
JNJ: 106.50 (-0.15), ABT: 39.18 (+0.36), IBM: 137.80 (unch), DGX: 69.32 (-0.39), LLY: 73.60 (+0.35), XRX: 10.50 (+0.10), ABBV: 56.15 (+0.22)
Jim Cramer -- Don't Underestimate Jobs Report Impact on Fed
at The Street - Fri Mar 04, 12:45PM CST
Jim Cramer considers the effect the strong jobs report may have on the Federal Reserve's plan to raise interest rates in 2016.
AEP: 62.43 (+0.66), WWAV: 41.15 (+0.60), JACK: 70.32 (+0.74), SWK: 98.59 (+1.08), LMT: 218.72 (+0.20), PNRA: 214.69 (-0.43), KHC: 77.20 (-0.17), TGT: 81.13 (+1.42), LLY: 73.60 (+0.35), WFC: 50.11 (+0.34), BAC: 13.54 (+0.04), DOW: 50.29 (+0.69), CSCO: 26.80 (-0.07)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 71.99 (-0.57), IMGN: 8.27 (+0.08), ARQL: 1.72 (-0.06), LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), ONTY: 1.21 (+0.05), MDVN: 40.44 (+2.24), MRK: 52.08 (-0.02), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), GALE: 0.98 (+0.03), PBYI: 48.94 (+2.23), NVS: 72.20 (-0.75), KPTI: 7.88 (+0.55), XLRN: 28.47 (+0.50), EXEL: 4.11 (+0.25)
Lilly to Participate in Barclays Global Healthcare Conference
PR Newswire - Wed Mar 02, 2:30PM CST
Eli Lilly and Company (NYSE:LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 16, 2016. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 3:20 p.m. Eastern Daylight Time.
LLY: 73.60 (+0.35)
TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical Research
Business Wire - Wed Feb 10, 7:30AM CST
TransCelerate BioPharma, Inc. announced today that it is launching BioCelerate, a new subsidiary that aims to improve efficiencies in preclinical research. The six initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd. Each of these organizations are also Member Companies of TransCelerate BioPharma, a condition for participation in BioCelerate, and will lead the first initiative, Toxicology Data Sharing, which will enable access to a broader cross-company set of toxicology data.
LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29)
Wharton Healthcare Conference to Be Headline by CEOs of Eli Lilly and Aledade
PRWeb - Tue Feb 09, 4:05PM CST
With a presidential election in November and the future of U.S. healthcare in the balance, the 2016 Wharton Health Care Business Conference will bring together over 500 top healthcare leaders for a night and day of debates and discussions about what lies ahead for an industry in transformation. The conference, organized by MBA students of the University of Pennsylvania's Wharton School, will be held February 18 - 19, 2016 at the Union League of Philadelphia.
LLY: 73.60 (+0.35)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29), ESPR: 17.32 (-0.01), AZN: 28.87 (+0.13), FGEN: 19.57 (+0.80), ARNA: 1.51 (-0.05)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 35.41 (+0.57), AMGN: 145.98 (+0.14), AMPE: 2.11 (-0.04), LLY: 73.60 (+0.35), ENZ: 4.14 (+0.07), CCXI: 3.44 (-0.03), ABBV: 56.15 (+0.22), ARNA: 1.51 (-0.05), CELGZ: 1.30 (-0.04)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.60 (+0.35), BIOD: 0.35 (+0.01), CLBS: 0.58 (-0.01), ARGS: 5.53 (+0.18), AZN: 28.87 (+0.13), CGEN: 5.87 (+0.30), ATHX: 1.78 (unch)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.53 (+0.10), DRNA: 6.02 (+0.43), INCY: 71.99 (-0.57), LLY: 73.60 (+0.35), STML: 5.68 (+0.16), SNTA: 0.25 (-0.01), ANTH: 3.75 (+0.12), EXEL: 4.11 (+0.25)
Dermatitis therapeutics Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/xxlb73/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Pipeline Products for Dermatitis - Overview - Pipeline Products for Dermatitis - Comparative Analysis - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Abeome Corporation - Accolade Pharma LLC - Aclaris Therapeutics, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Convoy Therapeutics, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Dr. August Wolff GmbH & Co. KG Arzneimittle - Eisai Co., Ltd. - Eli Lilly and Company - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Ziarco Pharma Ltd For more information visit http://www.researchandmarkets.com/research/xxlb73/dermatitis
CBPO: 110.00 (-0.70), DERM: 22.59 (+0.79), FOMX: 5.88 (-0.02), LLY: 73.60 (+0.35), ACRS: 18.02 (+0.69)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.72 (-0.06), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29), ATNM: 2.02 (+0.02), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), ABBV: 56.15 (+0.22), BXLT: 39.47 (+0.17), EXEL: 4.11 (+0.25), CELGZ: 1.30 (-0.04), ARRY: 3.00 (+0.04)
Credit Suisse Picks 7 Health Care Stocks to Own for the Next 6 Months
at The Street - Sat Feb 06, 12:00PM CST
Health care stocks are getting hit hard by the stock market turbulence of 2016. But these seven health care companies are worth owning, says Credit Suisse.
MDVN: 40.44 (+2.24), BSX: 17.44 (+0.03), HCA: 73.00 (+0.07), MCK: 162.77 (+0.07), UNH: 121.80 (-0.02), LLY: 73.60 (+0.35), CELG: 102.51 (-0.22)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.64 (+0.97), ARWR: 4.33 (+0.09), AMBX: (), CLDX: 8.19 (-0.06), ADMP: 5.77 (+0.04), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BIND: 1.79 (-0.02), BMY: 64.71 (-0.29), AZN: 28.87 (+0.13), ABBV: 56.15 (+0.22), CORT: 4.13 (+0.04)
Schizophrenia Market Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/65ggnc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schizophrenia Overview - Therapeutics Development - Pipeline Products for Schizophrenia - Overview - Pipeline Products for Schizophrenia - Comparative Analysis - Schizophrenia - Therapeutics under Development by Companies - Schizophrenia - Therapeutics under Investigation by Universities/Institutes - Schizophrenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schizophrenia - Products under Development by Companies - Schizophrenia - Products under Investigation by Universities/Institutes - Schizophrenia - Companies Involved in Therapeutics Development (Partial List) - Acadia Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - AgeneBio Inc. - Alkermes Plc - Amgen Inc. - Angita B.V. - ANP Technologies, Inc. - Astellas Pharma Inc. - Athersys, Inc. - BCWorld Pharm Co. Ltd. - BioCrea GmbH - Boehringer Ingelheim GmbH - Braeburn Pharmaceuticals, Inc. - Catalyst Biosciences, Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Delpor, Inc. - Dong Wha Pharma Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - Galenea Corp. - GeNeuro SA - Genovate Biotechnology Co., LTD. - Gilead Sciences, Inc. - Glenmark Pharmaceuticals Ltd. - GP Pharm, S.A. For more information visit http://www.researchandmarkets.com/research/65...izophrenia
ACAD: 21.20 (-0.26), GILD: 87.21 (-0.62), CBIO: 2.10 (+0.02), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), ATHX: 1.78 (unch), ALKS: 32.58 (-0.33)
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Sweta Killa - Zacks Investment Research - Fri Feb 05, 8:20AM CST
Despite the string of earnings beat, pharma stocks are suffering from the broad healthcare sector concerns.
IHE: 138.98 (-0.98), JNJ: 106.50 (-0.15), PPH: 58.26 (+0.01), PJP: 60.45 (-0.32), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XPH: 41.37 (-0.35), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29)
The Next Stock Warren Buffett May Sell
Todd Campbell, Dan Caplinger, and George Budwell, The Motley Fool - Motley Fool - Sat Mar 05, 6:21AM CST
Warren Buffett is legendary for his long-term buy-and-hold approach to investing, and as a result, investors big and small closely watch his buying and selling activity. There's no crystal ball that will tell all of us what his next move will be, but...
JNJ: 106.50 (-0.15), LLY: 73.60 (+0.35), SNY: 39.81 (+0.19), VZ: 51.81 (-0.08)
Novo Nordisk Pops As Diabetes Drug Cuts Heart Disease Deaths
at Investor's Business Daily - Fri Mar 04, 3:26PM CST
Shares of diabetes giant Novo Nordisk (NVO) jumped Friday after the company said its drug Victoza reduced heart attacks and strokes. Novo released few details about the results of the study, which it's saving for the next American Diabetes...
JNJ: 106.50 (-0.15), NVO: 56.75 (+4.15), MRK: 52.08 (-0.02), AZN: 28.87 (+0.13), LLY: 73.60 (+0.35), SNY: 39.81 (+0.19)
Ixekizumab Demonstrates Rapid, Clinically Meaningful Improvements as Early as One Week among Patients with Moderate-to-Severe Plaque Psoriasis
PR Newswire - Fri Mar 04, 3:15PM CST
Eli Lilly and Company (NYSE: LLY) announced today that treatment for moderate-to-severe plaque psoriasis with ixekizumab resulted in clinically meaningful improvements as early as one week, compared to patients treated with etanercept or placebo. Detailed results of this combined analysis of UNCOVER-2 and UNCOVER-3 were presented during the American Academy of Dermatology (AAD) Annual Meeting taking place March 4-8 in Washington, D.C.
LLY: 73.60 (+0.35)
Drug Company Executives Make the Best Connections
at The Street - Fri Mar 04, 2:07PM CST
An analysis from business information service BoardEx shows that the CEOs of healthcare and pharma companies have professional networks about 30% larger than the average S&P 500 CEO network.
JNJ: 106.50 (-0.15), ABT: 39.18 (+0.36), IBM: 137.80 (unch), DGX: 69.32 (-0.39), LLY: 73.60 (+0.35), XRX: 10.50 (+0.10), ABBV: 56.15 (+0.22)
Jim Cramer -- Don't Underestimate Jobs Report Impact on Fed
at The Street - Fri Mar 04, 12:45PM CST
Jim Cramer considers the effect the strong jobs report may have on the Federal Reserve's plan to raise interest rates in 2016.
AEP: 62.43 (+0.66), WWAV: 41.15 (+0.60), JACK: 70.32 (+0.74), SWK: 98.59 (+1.08), LMT: 218.72 (+0.20), PNRA: 214.69 (-0.43), KHC: 77.20 (-0.17), TGT: 81.13 (+1.42), LLY: 73.60 (+0.35), WFC: 50.11 (+0.34), BAC: 13.54 (+0.04), DOW: 50.29 (+0.69), CSCO: 26.80 (-0.07)
Endometrial Cancer Pipeline Market Research H2 2015 Report
PR Newswire - Wed Mar 02, 8:00PM CST
A market research report titled "Endometrial Cancer - Pipeline Review, H2 2015" provides an overview of the Endometrial Cancer's therapeutic pipeline and enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INCY: 71.99 (-0.57), IMGN: 8.27 (+0.08), ARQL: 1.72 (-0.06), LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), ONTY: 1.21 (+0.05), MDVN: 40.44 (+2.24), MRK: 52.08 (-0.02), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), GALE: 0.98 (+0.03), PBYI: 48.94 (+2.23), NVS: 72.20 (-0.75), KPTI: 7.88 (+0.55), XLRN: 28.47 (+0.50), EXEL: 4.11 (+0.25)
Lilly to Participate in Barclays Global Healthcare Conference
PR Newswire - Wed Mar 02, 2:30PM CST
Eli Lilly and Company (NYSE:LLY) will attend the Barclays Global Healthcare Conference on Wednesday, March 16, 2016. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 3:20 p.m. Eastern Daylight Time.
LLY: 73.60 (+0.35)
TransCelerate BioPharma Introduces New Subsidiary BioCelerate to Increase Efficiencies in Preclinical Research
Business Wire - Wed Feb 10, 7:30AM CST
TransCelerate BioPharma, Inc. announced today that it is launching BioCelerate, a new subsidiary that aims to improve efficiencies in preclinical research. The six initial biopharmaceutical companies committed to launching BioCelerate include Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd. Each of these organizations are also Member Companies of TransCelerate BioPharma, a condition for participation in BioCelerate, and will lead the first initiative, Toxicology Data Sharing, which will enable access to a broader cross-company set of toxicology data.
LLY: 73.60 (+0.35), GSK: 39.14 (-0.04), BMY: 64.71 (-0.29)
Wharton Healthcare Conference to Be Headline by CEOs of Eli Lilly and Aledade
PRWeb - Tue Feb 09, 4:05PM CST
With a presidential election in November and the future of U.S. healthcare in the balance, the 2016 Wharton Health Care Business Conference will bring together over 500 top healthcare leaders for a night and day of debates and discussions about what lies ahead for an industry in transformation. The conference, organized by MBA students of the University of Pennsylvania's Wharton School, will be held February 18 - 19, 2016 at the Union League of Philadelphia.
LLY: 73.60 (+0.35)
Global Obesity Pipeline Review, H2 2015 - Therapeutics Under Development by Leading Companies and Universities
M2 - Tue Feb 09, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/4fs2cn/obesity) has announced the addition of the "Obesity - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesityand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - ObesityOverview - Therapeutics Development - Pipeline Products for Obesity - Overview - Pipeline Products for Obesity - Comparative Analysis - Obesity - Therapeutics under Development by Companies - Obesity - Therapeutics under Investigation by Universities/Institutes - Obesity - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Obesity - Products under Development by Companies - Obesity - Products under Investigation by Universities/Institutes - Obesity - Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 35 Companies Featured - Abeome Corporation - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - Akron Molecules AG - Alize Pharma SAS - Amabiotics SAS - Ambrx, Inc. - Amgen Inc. - Arena Pharmaceuticals, Inc. - Arrien Pharmaceuticals, LLC - AstraZeneca Plc - Asubio Pharma Co., Ltd. - AtheroNova Inc. - Avaxia Biologics, Inc. - BioLingus AG - BioRestorative Therapies, Inc. - BioTime, Inc. - Boehringer Ingelheim GmbH - Braasch Biotech LLC - Bristol-Myers Squibb Company - Camurus AB - Carmot Therapeutics, Inc. - Chronos Therapeutics Limited - CohBar, Inc. - CoMentis, Inc. - Daiichi Sankyo Company, Limited - Deltanoid Pharmaceuticals Inc. - Diabetica Limited - DiscoveryBiomed, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Esperion Therapeutics, Inc. - Euroscreen S.A. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. For more information visit http://www.researchandmarkets.com/research/4fs2cn/obesity
AMBX: (), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29), ESPR: 17.32 (-0.01), AZN: 28.87 (+0.13), FGEN: 19.57 (+0.80), ARNA: 1.51 (-0.05)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 35.41 (+0.57), AMGN: 145.98 (+0.14), AMPE: 2.11 (-0.04), LLY: 73.60 (+0.35), ENZ: 4.14 (+0.07), CCXI: 3.44 (-0.03), ABBV: 56.15 (+0.22), ARNA: 1.51 (-0.05), CELGZ: 1.30 (-0.04)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.60 (+0.35), BIOD: 0.35 (+0.01), CLBS: 0.58 (-0.01), ARGS: 5.53 (+0.18), AZN: 28.87 (+0.13), CGEN: 5.87 (+0.30), ATHX: 1.78 (unch)
Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 2.53 (+0.10), DRNA: 6.02 (+0.43), INCY: 71.99 (-0.57), LLY: 73.60 (+0.35), STML: 5.68 (+0.16), SNTA: 0.25 (-0.01), ANTH: 3.75 (+0.12), EXEL: 4.11 (+0.25)
Dermatitis therapeutics Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/xxlb73/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dermatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dermatitis Overview - Therapeutics Development - Pipeline Products for Dermatitis - Overview - Pipeline Products for Dermatitis - Comparative Analysis - Dermatitis - Therapeutics under Development by Companies - Dermatitis - Therapeutics under Investigation by Universities/Institutes - Dermatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dermatitis - Products under Development by Companies - Dermatitis - Products under Investigation by Universities/Institutes - Dermatitis - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Abeome Corporation - Accolade Pharma LLC - Aclaris Therapeutics, Inc. - China Biologic Products, Inc. - ChironWells GmbH - Chugai Pharmaceutical Co., Ltd. - Convoy Therapeutics, Inc. - Creabilis SA - Delenex Therapeutics AG - Dermira Inc. - Dr. August Wolff GmbH & Co. KG Arzneimittle - Eisai Co., Ltd. - Eli Lilly and Company - EpiPharm AG - F. Hoffmann-La Roche Ltd. - FAES Farma SA - Foamix Pharmaceuticals Ltd. - Ziarco Pharma Ltd For more information visit http://www.researchandmarkets.com/research/xxlb73/dermatitis
CBPO: 110.00 (-0.70), DERM: 22.59 (+0.79), FOMX: 5.88 (-0.02), LLY: 73.60 (+0.35), ACRS: 18.02 (+0.69)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.72 (-0.06), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29), ATNM: 2.02 (+0.02), AZN: 28.87 (+0.13), AVEO: 1.00 (-0.02), ABBV: 56.15 (+0.22), BXLT: 39.47 (+0.17), EXEL: 4.11 (+0.25), CELGZ: 1.30 (-0.04), ARRY: 3.00 (+0.04)
Credit Suisse Picks 7 Health Care Stocks to Own for the Next 6 Months
at The Street - Sat Feb 06, 12:00PM CST
Health care stocks are getting hit hard by the stock market turbulence of 2016. But these seven health care companies are worth owning, says Credit Suisse.
MDVN: 40.44 (+2.24), BSX: 17.44 (+0.03), HCA: 73.00 (+0.07), MCK: 162.77 (+0.07), UNH: 121.80 (-0.02), LLY: 73.60 (+0.35), CELG: 102.51 (-0.22)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.64 (+0.97), ARWR: 4.33 (+0.09), AMBX: (), CLDX: 8.19 (-0.06), ADMP: 5.77 (+0.04), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), BIND: 1.79 (-0.02), BMY: 64.71 (-0.29), AZN: 28.87 (+0.13), ABBV: 56.15 (+0.22), CORT: 4.13 (+0.04)
Schizophrenia Market Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/65ggnc/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Schizophrenia Overview - Therapeutics Development - Pipeline Products for Schizophrenia - Overview - Pipeline Products for Schizophrenia - Comparative Analysis - Schizophrenia - Therapeutics under Development by Companies - Schizophrenia - Therapeutics under Investigation by Universities/Institutes - Schizophrenia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Schizophrenia - Products under Development by Companies - Schizophrenia - Products under Investigation by Universities/Institutes - Schizophrenia - Companies Involved in Therapeutics Development (Partial List) - Acadia Pharmaceuticals Inc. - Aequus Pharmaceuticals Inc. - Aestus Therapeutics, Inc. - AgeneBio Inc. - Alkermes Plc - Amgen Inc. - Angita B.V. - ANP Technologies, Inc. - Astellas Pharma Inc. - Athersys, Inc. - BCWorld Pharm Co. Ltd. - BioCrea GmbH - Boehringer Ingelheim GmbH - Braeburn Pharmaceuticals, Inc. - Catalyst Biosciences, Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Delpor, Inc. - Dong Wha Pharma Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company - Evotec AG - F. Hoffmann-La Roche Ltd. - FORUM Pharmaceuticals Inc. - Galenea Corp. - GeNeuro SA - Genovate Biotechnology Co., LTD. - Gilead Sciences, Inc. - Glenmark Pharmaceuticals Ltd. - GP Pharm, S.A. For more information visit http://www.researchandmarkets.com/research/65...izophrenia
ACAD: 21.20 (-0.26), GILD: 87.21 (-0.62), CBIO: 2.10 (+0.02), AMGN: 145.98 (+0.14), LLY: 73.60 (+0.35), ATHX: 1.78 (unch), ALKS: 32.58 (-0.33)
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Sweta Killa - Zacks Investment Research - Fri Feb 05, 8:20AM CST
Despite the string of earnings beat, pharma stocks are suffering from the broad healthcare sector concerns.
IHE: 138.98 (-0.98), JNJ: 106.50 (-0.15), PPH: 58.26 (+0.01), PJP: 60.45 (-0.32), MRK: 52.08 (-0.02), PFE: 29.71 (-0.18), XPH: 41.37 (-0.35), LLY: 73.60 (+0.35), BMY: 64.71 (-0.29)
